A detailed history of Bank Of Montreal transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Bank Of Montreal holds 354,813 shares of ABUS stock, worth $1.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
354,813
Previous 334,265 6.15%
Holding current value
$1.32 Million
Previous $862,000 27.15%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.52 - $3.63 $51,780 - $74,589
20,548 Added 6.15%
354,813 $1.1 Million
Q1 2024

May 13, 2024

SELL
$2.26 - $2.92 $40,679 - $52,560
-18,000 Reduced 5.11%
334,265 $862,000
Q4 2023

Feb 08, 2024

BUY
$1.69 - $2.54 $54,216 - $81,485
32,081 Added 10.02%
352,265 $880,000
Q3 2023

Nov 01, 2023

SELL
$1.9 - $2.27 $205,369 - $245,362
-108,089 Reduced 25.24%
320,184 $649,000
Q2 2023

Aug 02, 2023

BUY
$2.24 - $3.06 $242,995 - $331,948
108,480 Added 33.92%
428,273 $985,000
Q1 2023

Jun 13, 2024

SELL
$2.23 - $3.1 $37,486 - $52,111
-16,810 Reduced 5.03%
317,455 $961,000
Q4 2022

Feb 01, 2023

SELL
$1.91 - $2.85 $401 - $598
-210 Reduced 0.07%
319,793 $745,000
Q3 2022

Nov 10, 2022

SELL
$1.88 - $2.88 $15,902 - $24,361
-8,459 Reduced 2.58%
320,003 $707,000
Q2 2022

Aug 11, 2022

BUY
$1.98 - $3.17 $19,566 - $31,325
9,882 Added 3.1%
328,462 $869,000
Q1 2022

May 12, 2022

BUY
$2.42 - $3.98 $197,767 - $325,253
81,722 Added 34.5%
318,580 $953,000
Q4 2021

Feb 11, 2022

BUY
$3.11 - $4.61 $75,563 - $112,009
24,297 Added 11.43%
236,858 $921,000
Q3 2021

Nov 12, 2021

SELL
$2.65 - $4.62 $104,622 - $182,397
-39,480 Reduced 15.66%
212,561 $910,000
Q2 2021

Aug 12, 2021

BUY
$2.5 - $3.51 $630,102 - $884,663
252,041 New
252,041 $796,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $559M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.